PlaqueTec has appointed Annalisa Jenkins its CEO. She will lead the company's launch in 2018 of its biomarker-based PlaqueTec Liquid Biopsy System, which is being developed to improve risk assessment and enable earlier intervention in the management of coronary artery disease. The system collects biomarkers directly associated with plaques whtin coronary arteries in order to assess residual inflammatory risk. Jenkins formerly was the CEO of Dimension Therapeutics. Prior to that, she was Executive Vice President, Head of Global R&D for Merck Serono.